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Abstract
Introduction: Mathematical modelling of Clostridium difficile infection dynamics could contribute to the optimisation
of strategies for its prevention and control. The objective of this systematic review was to summarise the available
literature specifically identifying the quantitative parameters required for a compartmental mathematical model of
Clostridium difficile transmission.
Methods: Six electronic healthcare databases were searched and all screening, data extraction and study quality
assessments were undertaken in duplicate. Results were synthesised using a narrative approach.
Results: Fifty-four studies met the inclusion criteria. Reproduction numbers for hospital based epidemics were
described in two studies with a range from 0.55 to 7. Two studies provided consistent data on incubation periods. For
62% of cases, symptoms occurred in less than 4 weeks (3-28 days) after infection. Evidence on contact patterns was
identified in four studies but with limited data reported for populating a mathematical model. Two studies, including
one without clinically apparent donor-recipient pairs, provided information on serial intervals for household or ward
contacts, showing transmission intervals of <1 week in ward based contacts compared to up to 2 months for
household contacts. Eight studies reported recovery rates of between 75% - 100% for patients who had been treated
with either metronidazole or vancomycin. Forty-nine studies gave recurrence rates of between 3% and 49% but were
limited by varying definitions of recurrence. No study was found which specifically reported force of infection or net
reproduction numbers.
Conclusions: There is currently scant literature overtly citing estimates of the parameters required to inform the
quantitative modelling of Clostridium difficile transmission. Further high quality studies to investigate transmission
parameters are required, including through review of published epidemiological studies where these quantitative
estimates may not have been explicitly estimated, but that nonetheless contain the relevant data to allow their
calculation. [Systematic review reference: CRD42012003081]
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Introduction
Clostridium difficile (C. difficile) infection (CDI) is a
considerable public health problem with over 20,000 cases in
the UK and up to 300,000 in the US annually [1]. In the last
decade, new strains of and epidemiological changes in existing
strains of the organism have emerged, in particular ribotype
027. This highly pathogenic ribotype has resulted in substantial
morbidity and mortality [1-3]. CDI results in diarrhoea which
ranges in severity from mild to severe, which in life threatening
cases may require surgery [1] . Outbreaks of CDI have
occurred in a wide range of healthcare settings including acute
care hospitals, nursing homes, intensive care units, as well as
in community settings. These have caused considerable
political and public disquiet and have spurred government-
driven action to address this organism both in the UK and
internationally [3]. However, much remains unknown regarding
the factors which influence CDI acquisition and transmission,
therefore potentially compromising the development of effective
interventions and control policies.
Transmission of C. difficile from hospitalised, symptomatic
cases was previously thought to be the primary source of
disease; however a recent hospital based study has shown that
transmission from these cases accounts for no more than 25%
of new hospital cases [2]. Asymptomatic carriage or
colonisation in both patients and healthcare workers, or
infection from other community sources entering the hospital,
may have relevance to propagation within the healthcare
environment [4,5]. However, uncertainties in attributing
acquisition to the community or from within the hospital setting,
coupled with limitations in microbiological testing methods,
complicates understanding of the routes of transmission and
acquisition [6-8].
CDI has in recent years been noted among groups
previously considered to be at low risk of acquiring the disease
including young adults, pregnant women and people without
apparent prior exposure to antibiotics or healthcare facilities [9].
The possibility of food-borne acquisition of C. difficile, through
contact with companion animals, infants and aerosolised faecal
material has been suggested [10-13].
It is apparent that the mechanisms of C. difficile transmission
are complex. Mathematical modelling could be a useful tool to
improve our understanding of CDI dynamics, as has been
shown for other complex infectious diseases such as influenza
[14]. Such models could make a valuable contribution to
optimising CDI management and control; for example by
providing theoretical frameworks to model and monitor the
spread of infection, to improve the understanding of the
underlying factors that trigger the development of epidemics
from sporadic cases, to predict future trends and for testing the
effects of intervention strategies.
Objectives
We undertook a systematic review to collate and summarise
the available literature where the quantitative estimates of the
mathematical parameters required to inform the development
of a SEIRS (susceptible, exposed [pre-infectious], infectious,
recovered [immune], susceptible [second susceptible])
compartmental transmission model for CDI are explicitly stated.
Methods
This review was carried out in accordance with PRISMA
guidelines. A completed PRISMA checklist is available (Table
S1). The full study protocol is registered with the National
Institute for Health Research international prospective register
of systematic reviews (PROSPERO) - registration number:
CRD42012003081 [15]. Minor subsequent protocol
amendments were submitted to clarify the study populations
and eligibility criteria. This systematic review of the
mathematical parameters needed to model CDI is a necessary
prerequisite to the development of theoretical frameworks that
can represent the infection dynamics of this organism. A further
systematic review of the epidemiological characteristics
(infection rates and risk factors) of CDI will also be required.
Search strategy and study selection
We searched six electronic databases: EMBASE
(1980-2012), Medline (1946-2012), PubMed (1920-2012), Web
of Science (1899-2012), CINAHL (1968-2012) and the
Cochrane database of systematic reviews to identify all
epidemiological studies and evidence based reviews assessing
transmission and acquisition of CDI. Further publications and
grey literature were identified through internet searches of
relevant websites (World Health Organisation, European
Centre for Disease Prevention and Control, UK Health
Protection Agency, UK Department of Health, US Centres for
Disease Control and Prevention, Public Health Agency of
Canada, Centre for Health Protection, Hong Kong, National
Institute of Infectious Diseases Japan and Chinese Centre for
Disease control and Prevention) [15]. Keywords relating to
‘Clostridium difficile’, ‘epidemiology’, ‘transmission’ and each of
the relevant mathematical parameters were used to identify
relevant papers. Search terms were developed through
discussion and consensus and piloted in each individual
database before the formal search process. Where available,
medical subject headings (MeSH) were defined for the
population and outcome parameters and adapted in
accordance with the specifications of each search engine.
The final electronic search was performed on 8 October
2012. In addition, we performed reference and citation tracking
of all included papers to further identify unpublished literature.
No year limitations were applied. Studies in languages other
than English were only considered if an English abstract was
available.
Eligibility criteria
Studies meeting all the following key criteria were included in
the review:
1. Study design: Any experimental and observational
studies assessing C.difficile transmission or acquisition
2. Population: persons of any age with laboratory-
confirmed CDI whether symptomatic or asymptomatic
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3. Outcome measures: studies specifically reporting
parameters required to create a SEIRS type mathematical
model of CDI, i.e. basic reproduction number, net
reproduction number, incubation period, and contact
pattern, force of infection, serial interval and duration of
infectiousness, recovery rate and recurrence rates [16]
After excluding duplicates, a three-stage filter process
(assessment of titles, abstracts and full text) was used to
screen all identified studies against the eligibility criteria. At
each stage the screening was managed using Endnote X4 ®
(Thomson Reuters, California, USA). Screening was
undertaken independently by two out of three reviewers (AA,
HJ and EHO) with consensus by discussion and provision for
arbitration by a third reviewer.
Data extraction
Data were extracted independently by two reviewers from
each included study using a pre-defined piloted template.
Disagreements were resolved through discussion with
provision for arbitration by a third reviewer. Data extracted on
study characteristics comprised design, country, time period,
objectives, number of participants and method of subject
selection, diagnostic method and inclusion/exclusion criteria.
Data obtained on population characteristics were; subgroup
studied, study setting, age, sex, co-morbidities and race/
ethnicity. Outcome measures extracted were; basic
reproduction number, net reproduction number, incubation
period, contact pattern, force of infection, serial interval and
duration of infectiousness, recovery rate, recurrence rate and
definition of recurrence. No further data were requested from
authors of included studies. (Definitions of the mathematical
terms are listed in Table S4).
Quality assessment
The quality of included studies was was assessed using only
the Newcastle Ottawa Scale (NOS) for observational studies
since no experimental studies were found. Consensus was
reached by discussion, with arbitration by a third reviewer as
necessary [17]. Studies were judged on three domains i)
selection criteria of subjects, ii) comparability of subjects
(adjustment for confounders) and iii) ascertainment of the
exposure or outcome of interest, with a maximum total score of
9 for cohort or case-control studies and 7 for cross-sectional
studies. A high score across all three assessment domains
(participant selection, adjustment for confounders and
ascertainment of outcome) suggests the study is of higher
quality than those scoring at lower points on the scale. The
paucity of information available from abstract-only manuscripts
precluded assessment of quality for these studies.
Summary measures
Both the quality and data extraction findings were tabulated
and synthesised qualitatively using a narrative approach in
accordance with the framework described by the Economic and
Social Research Council and recommended by the University
of York Centre for Reviews and Dissemination.
Results
Study Selection
We identified 17, 935 articles; 16,963 from healthcare
databases and the rest from other sources (Figure 1). After de-
duplication, reference tracking and exclusion of studies that did
not fit the inclusion criteria (at title and abstract review), 91
studies reporting mathematical modelling parameters for CDI
were identified for full text review. A further 37 articles were
excluded (Figure 1). Two of the included articles were from a
single retrospective study but reported outcomes from different
population subgroups so both were separately retained [18,19].
Overall, 54 full text articles were included in the narrative
synthesis.
Description of included studies
The characteristics of the 54 studies which met the protocol
eligibility criteria are summarised in Table 1 with further detail
provided in Table S2. All identified studies were observational
(55% [n=32] cross-sectional, 26% [n=14] cohort, 11% [n=6]
case-control studies and in 4% [n=2] the study design was
unclear). Data were reported on at least 26,137 subjects with
CDI (the numbers included in one study were unclear). The
number of subjects with CDI in individual studies ranged from 9
to 14,329 and four studies each made use of large hospital
laboratory databases with over 1,000 CDI cases [20-23].
The characteristics of populations investigated varied
substantially. Studies were reported from at least 17 different
countries including USA (n= 23), Europe (n=13), South Korea
(n=6) and Canada (n=3). There was wide age variability across
most study populations (age range: 1 month to 99 years) but
some focused solely on children or adults [19,22,24-31]. The
majority of studies (n=34) included hospital in-patients with no
other specified co-morbidities, but 16 were from within specific
specialties or investigating patients with defined medical
conditions. Whilst 21 studies investigated non-specific
populations of hospitalised patients alone, the rest either
combined both inpatients and outpatients, hospital inpatients
with nursing home residents or patients diagnosed with CDI
within a circumscribed geographical area [18-21,23,32-37].
Quality assessment
The majority of studies included were judged to have low
scores on the NOS. Among cross-sectional studies, scores
ranged from one to seven [37,38]. In the case-control and
cohort studies, scores ranged from three to seven
[25,33,35,39-41]. Inadequate matching and adjustment for
confounders was responsible for the lower quality assessment
scores attained. Only two cross-sectional studies and one
cohort study reported having adjusted for other confounding
variables [38,42,43]. For most case-control studies, use of
hospital control subjects resulted in lower quality assessment
scores because NOS defines that only the use of community
controls warrants a positive score since hospital controls may
have other co-morbidities that could influence study outcomes.
Although 4 out of 6 case control studies attempted to match
hospital controls to cases by sex, month of diagnosis, antibiotic
Modelling Parameters for C.diff: Systematic Review
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Figure 1.  PRISMA flow diagram of the literature review process.  
doi: 10.1371/journal.pone.0084224.g001
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exposure or propensity score, it was unclear whether this was
adequate to control for bias [32,44-46].
Other methodological concerns which resulted in poor quality
assessment scoring were related to insufficient information on
follow-up – 10 of 14 cohort studies, inadequate definitions of
study outcomes - particularly for studies reporting recurrence
and use of suboptimal testing techniques for CDI detection.
For 5 studies, no quality assessment could be performed
because a full English translation of the article was unavailable
[47-51]. For one study in which the study design was unclear,
the quality assessment was made assuming it was a cross-
sectional study [52].
Synthesis of Results
Reproduction number.  Only one hospital-based study
reported estimates for the reproduction number based on a
Table 1. Summary of study characteristics for included
studies (N=54).
Characteristic
Number of
studies % of studies
Study design   
Cross-sectional studies 32 59
Case-control studies 6 11
Prospective cohort studies 14 26
Design unclear 2 4
Country (UN inequality-adjusted Human
Development Index 2010)   
Very high 47 87
High 1 2
Medium/low 0 0
Data unclear 6 11
Study population/specific subgroups *   
Hospital inpatients (general/unspecified) 34 63
Hospital outpatients (general/unspecified) 20 37
Nursing/long-term care facility 5 9
All community cases within a circumscribed area 3 6
Renal patients 2 4
Organ/stem cell transplant patients 6 11
Other – HIV, neurology and psychiatric
gerontology, surgery / gastroenterology,
appendectomy, burns, gynaecological oncology,
IBD
8 15
Method of laboratory diagnosis @   
Toxin detection / immune assay 51 94
Stool culture 18 33
Polymerase chain reaction (PCR) ribotyping 6 11
Antigen detection 1 2
Multilocus sequence typing 1 2
Laboratory-diagnosed, methods unclear 2 2
* Numbers do not sum to 54 as some studies include more than one population
group
@ Numbers do not sum to 54 as some studies include more than one method of
diagnosis
doi: 10.1371/journal.pone.0084224.t001
non-linear transmission model [42]. Another used ribotyping to
estimate strain-dependent numbers of secondary cases per
index case (Table 2) [34]. The study by Lanzas et al comprised
11,406 patients across 6 medical wards and was used to
estimate parameters of a compartmental mathematical model
for C. difficile transmission [42]. Hosts were classified as
susceptible if they had received antimicrobial treatment. Those
who had not been on antibiotic treatment were presumed to be
resistant to colonisation. Infectious hosts were either diseased
(D) (i.e. manifesting CDI), asymptomatically colonised with
protection (C+) (mounted an immune response) or
asymptomatically colonised without protection (C-) (no immune
response mounted) [42]. The basic reproduction number (R0)
(defined in this context as the average (median) number of
secondary colonisations (C+ or C-) per colonisation (C+ or C-)
or infection (D) in a ward free from CDI) was estimated at 1.04
(range: 0.55-1.99), with each host (susceptible C+ or C- or
infected D) generating on average 0.4 colonised hosts without
protection (C-) and 0.6 colonised hosts with protection (C+).
Noren et al reported higher rates of secondary cases than
Lanzas (335 C. difficile-infected patients from three hospitals
[two tertiary care, one primary care]), although without
accounting for non-linear transmission effects or the proportion
of patients asymptomatically colonised, these estimates cannot
be directly mapped to R0 [34,42]. The reported secondary case
rates were strain-specific. Amongst the 8 strains identified,
Swedish ribotype SE 17 (UK ribotype 012) appeared to pose
the highest risk of transmission (mean 2.6 secondary cases per
index case [range 1 to 7]). C. difficile types 11 (081) and 12
(002/159/183) had the lowest secondary case rate (1
secondary case per index case), while ribotypes 7b (054), 20
(001), 21 (014/077/020/220), 21b (014/077/020/220) and 23a
(258) generated at least 1.2 cases [34]. Both studies
investigating the reproduction number of CDI scored highly on
the quality assessments. (Swedish ribotype, UK ribotype
taxonomy matching – Personal communication, T Akerlund,
Swedish Institute for Communicable Disease Control, October
2013)
Incubation period.  Two hospital-based studies with
estimates of incubation periods for CDI were found (Table 3)
[2,53]. Although the studies were substantially different in terms
of study size, study period and diagnostic technique, each
estimated similar incubation periods of <4 weeks for the most
probable transmission links of all identified “index case -
secondary case” pairs. In the study by Samore, all 12 in-
patients studied over a 2 month period became symptomatic 3
- 28 days (median 19 days) after exposure to infection from a
symptomatic index case [53]. Walker et al, reported estimated
incubation periods for three types of possible transmission
links, the most plausible directional potential transmission links:
Median incubation period 18, (range 8–42) days, the most
plausible links: 24 (10–61) days and all potential links: 33 (13–
74) days [2]. Both of these investigations achieved high NOS
quality assessment scores, although neither explored the
effects of potential confounding factors; in particular it is
possible that the incubation period could be influenced by other
factors within the host. Both studies were undertaken in a
Modelling Parameters for C.diff: Systematic Review
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hospital setting so limiting their generalizability to community
associated infection.
Contact patterns.  The nature of the contact implicated in C.
difficile transmission was reported in three studies; hospital
ward-based contacts and contacts between household
members [20,38,53]. Results are shown in Table 4. These
demonstrated the likelihood that C. difficile could spread from
an infected individual to their ward-based or household
contacts. Information reported in the household study was
limited to relative risks [20]. Pepin et al, showed that child
contacts of an infected individual had a higher risk of being
infected than spouse contacts (relative risk, child: 90.61 [95%
CI: 33.89 - 487.64] vs. spouse: 7.61 [95% CI: 5.77-9.78]),
however there were few child contacts on which this estimate
was based [20]. Information on ward based contact was limited
to the duration of contact that could facilitate transmission
(adjusted hazard ratio per daily roommate exposure: 1.11 [95%
C.I 1.03-1.19]) [38].
The study by Pepin et al (2012) achieved the lowest NOS
quality score [20]. The authors were unable to prove donor-
recipient linkages, and thus the strength of evidence for the
reported risk for household contacts is questionable since
‘secondary infection’ in the household may not necessarily be
attributable to the index household case.
Force of infection.  No studies describing the force of
infection were identified.
Serial Interval.  The serial interval of CDI was reported for
household and hospital contacts in two studies (Table 5) [2,20].
There was some variability in reported intervals which may
reflect differences in study settings and methods. One study
suggested that the serial interval of CDI in a hospital setting is
likely to be <1 week but in some circumstances could be up to
8 weeks [2]. The second study reported serial intervals in
household settings ranging from 6 to 50 days and in one
situation up to 186 days [20]. Although the lower limits reported
in the second study correspond to that of the first, this study
utilised a small cluster of cases and achieved a low NOS
quality score.
Recovery rate.  The recovery rate from CDI was reported in
eight studies (Table 6) [22,26,31,32,51,54-56]. Recovery was
typically dependent on treatment with antimicrobials (either
metronidazole or vancomycin). Two studies reported data on
immune-compromised patients and both found similar recovery
rates of 98% and 100% [31,56]. Five studies reported data on
non-specific groups of hospital inpatients with recovery rates
ranging from 75% to 94%. The lowest recovery rate of 56%
was found in the only study which estimated recovery for both
patients who had received any treatment for CDI and those
who received none. Other studies typically estimated separate
recovery rates for treated and untreated patients. Three of the
studies were judged to have low NOS quality scores due to one
or all of the following reasons: unclear definitions of recovery,
lack of information on how recovery was ascertained and
Table 3. Studies reporting data on incubation period.
Author Year Study details Study Period Incubation Period Data
Samore
[53] 1996
52 ‘index’ cases with
diarrhoea and positive
stool toxin assay were
included; stool
samples from hospital
roommates, occupants
of adjacent wards and
the patient
subsequently
occupying the room
were analysed for
evidence of
transmission
June to
December
1992
Interval between onset
of exposure and onset
of symptoms in 12
symptomatic contacts:
3-28 days, median 19
days. Interval between
onset of exposure and
positive culture in 19
asymptomatic contacts:
1-20 days, median 5
days
Walker
[2] 2012
Data of 218 enzyme
immune assay positive
patients from a
hospital laboratory
database were used to
analyse potential ward-
based contacts
between patients
September
2007 to
March 2010
Incubation periods
calculated: 61% of
patients <=4wks. 13% of
patients >12wks.
Medians 18-33 days
depending on possible
links. IQRs 8-74 days,
depending on possible
links
doi: 10.1371/journal.pone.0084224.t003
Table 2. Studies providing limits on basic reproduction number.
Author Year Study details Study Period Basic Reproduction Number Data
Lanzas
[42] 2011
A mathematical model for C.difficile transmission which
identifies hosts who have received antimicrobial treatment as
susceptible, and distinguishes between diseased,
asymptomatically colonised hosts with protection and
asymptomatically colonised hosts without protection, was fitted
to a hospital data set comprising 11046 patients in which
diagnosis was by stool toxin
January to
December 2008
Estimated basic reproduction numbers for variation in other
parameters: Mean= 1.07, Median= 1.04. Range 0.55-1.99. New
colonisations produced by asymptomatic or symptomatic patients’
averaged 0.4 new patients colonised without a protective response
and 0.6 new patients colonised with a protective response
Noren
[34] 2004
330 isolates from patients with toxin-positive diarrhoea were
analysed by PCR ribotyping Secondary cases were linked to
index cases using PCR ribotyping
February 1999 to
January 2000
For ribotype SE17 (UK ribotype 012), 7 index cases gave rise to 19
secondary cases. Mean: 2.6 secondary cases per index case
(range 1-7). For ribotypes other than SE17: Mean 1.2 secondary
cases per index case (range 1-4)
doi: 10.1371/journal.pone.0084224.t002
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insufficient follow up data [31,54,55]. Of the others, three were
judged to be of good quality on the basis of clear definitions
and the use of consistent methods of ascertaining recovery
[22,26,32].
Table 4. Studies reporting data on contact patterns.
Author Year Study details Study Period Contact Pattern Data
Hamel [38] 2010
Multiple databases of 37697 patients used to identify 202
cases of CDI (identified by enzyme immunoassay for toxin
A or B) and room-mate exposures.
April 2001 to
March 2006.
Total roommate exposure was associated with CDI - Hazard
Ratio (HR) total roommates/day 1.06 (1.00-1.12). After
adjusting for confounders, HR=1.11 (1.03-1.19).
Pepin [20] 2012
2222 patients diagnosed with CDI were identified from a
hospital database. Cases related to one another were
found and verified using telephone number.
January 1998 to
December 2009.
5/1061 spouses and 3/501 children developed CDI. Attack
rates were 4.71/1000 and 5.99/1000 respectively.
Samore
[53] 1996
52 ‘index’ cases with diarrhoea and positive stool toxin
assay were included; stool samples from hospital
roommates, occupants of adjacent wards and the patient
subsequently occupying the room were analysed for
evidence of transmission.
June to December
1992.
99 contacts were analysed; 12 had C. difficile diarrhoea, 19
were asymptomatically colonised. Typing showed that only 6
of these contacts (5 symptomatic, 1 asymptomatic) had the
identical strain to the index case. 42% of the index cases had
at least 1 positive contact.
doi: 10.1371/journal.pone.0084224.t004
Table 5. Studies reporting time interval between infection and onward transmission.
Author Year Study details Study Period Serial Interval Data
Pepin [20] 2012
2222 patients diagnosed with CDI were identified from a
hospital database. Cases related to one another were found
and verified using telephone number.
January 1998 to
December 2009.
9 household contacts with CDI: 8/9 secondary cases developed
within 2 months of the index case.
Walker [2] 2012
Data of 218 EIA positive patients from a hospital laboratory
database were used to analyse potential ward-based
contacts between patients.
September 2007 to
March 2010.
Minimum infectious period: 65% of transmissions ≤ 1wk, 82% ≤
4wks, 10% > 8wks. Medians 1-8 days depending on possible
links. IQRs 0-33 days, depending on possible links.
doi: 10.1371/journal.pone.0084224.t005
Table 6. Studies reporting data on recovery rate.
Author / Year Year Study subgroup Study Period Recovery Rate Data
Alanazi [31] 2012
Pediatric patients undergoing
hemopoietic stem cell
transplantation
2001-2009 Responded to therapy with metronidazole: 78/80 (98%).
Bilgrami [56] 1999 Blood stem cell transplantpatients Mar 1993- Aug 1996
Recovered after initial therapy with metronidazole and/or vancomycin: 14/14 (100%) -
1 patient had a relapse but recovered afterwards.
Bouza [51] 1995 Hospital inpatients 1994 (one year) Recovered after initial therapy (oral vancomycin or metronidazole): 76/83 (92%)
Khan [26] 2012 Hospital inpatients (≥15 years) 2006-2009 Cure rate (resolution of diarrhoea by day 6 of treatment, and negative assays on days6 and 10): 96/123 (78%).
Kim [55] 2011 Hospital inpatients Sep 2008-Jan 2010 Diarrhoea stopped without treatment: 49/189 (26%). Clinical cure rate (with treatment):118/140 (84%). ‘Global cure’ i.e. cured without recurrence: 93/140 (66%).
Kim [22] 2012 Adult hospital inpatients (>18years) 2004-2008
2008 cohort - ‘Improved' without therapy other than discontinuing antibiotics: 235/1367
(17%) – (NB the 1367 quoted includes patients who went on to have treatment).
‘Improved' with oral metronidazole: 796/846 (94%).
Kyne [54] 1998 Hospital inpatients Jan-Jun 1995 Resolution of symptoms: 38/73 (52%). Of the 73 patients, 62 had had metronidazole orvancomycin therapy, 11 had no treatment.
Vesteinsdottir [32] 2012
All patients in Iceland (hospital-
acquired and community-
acquired CDI)
July 2010-June 2011 Recovery rate from primary CDI with 1 course of antibiotics: 70/93 (75%) – 69 patientshad metronidazole, 1 had vancomycin.
doi: 10.1371/journal.pone.0084224.t006
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Recurrence rate.  Forty-nine studies reported recurrence of
CDI data (Table S3) [18,19,21-30,32-37,39-41,43-52,54-70].
Rates ranged from 3 to 49% with variation by study population.
Two studies investigated recurrence in circumscribed
populations that comprised all hospital and community cases
[32,34]. For studies considering only hospitalised patients,
recurrence rates ranged from 3 to 36% were observed
although it should be noted that the study reporting 3% was
based on only 14 patients [59]. The highest proportion of
recurrence was found among the elderly (35 - 39%), those
resident in long-term care (up to 49%) or patients diagnosed
with gastrointestinal related illnesses (45%) [48,58,60,69]. The
generalizability of these findings is compromised by the
variable definitions used for recurrence across the different
studies.
Summary measures.  No statistical pooling of results was
undertaken because of the extensive heterogeneity of identified
studies.
Discussion
To our knowledge, this is the first systematic review
undertaken to assess the evidence base on the mathematical
parameter estimates required for modelling the infection
dynamics of C. difficile. The study was designed to only search
for studies that specifically estimated and reported on one or
more of the quantitative parameters required to inform a SEIRs
compartmental transmission model. Our summary of the
evidence has identified that there is a paucity of literature
available explicitly reporting the mathematical parameters
which describe the transmission and acquisition of C. difficile.
This probably reflects a lack of attention of the infectious
diseases modelling community to this important disease. It is
however likely that published epidemiological studies will
contain suitable data from which these quantitative parameters
can be estimated, even where these have not be explicitly
stated. For example, the generation time and serial interval are
composite quantities determined by the incubation period
distribution and infectiousness over time in infected individuals.
Nonetheless, the paucity of information available on the
parameters required to construct suitable infectious disease
models is an important finding in itself. Given the substantial
burden posed by CDI, the near absence of published estimates
with which to model CDI and therefore by implication the likely
paucity of modelling activity is perhaps surprising and a missed
opportunity.
Limited evidence was identified on the reproduction
numbers. A single study used a non-linear transmission model
to estimate R0 and whilst point estimates for this threshold
parameter were above one, the data were consistent with
values below one [42]. However, it is important to note in this
study by Lanzas et al, that the definition of colonization used by
the research only includes those recently exposed to
antibiotics. It therefore ignores those who may be carrying the
organism asymptomatically but who nonetheless could be
shedding it. Rates of secondary infection also indicated that
transmission from infected patients alone may not sustain new
cases of CDI within hospitals. This complements the results of
a recent study by Walker et al (2012) that suggest that only
about 25% of new hospital cases arise from patient-to-patient
transmission within hospital wards [2]. Noren et al, reported
that some strains appeared to be more likely to generate new
cases than others [34]. Given experience with other infectious
diseases, this finding is not surprising, e.g. meningococcal
disease [71]. It is therefore possible that the transmission
dynamics of C. difficile will vary by setting and strain. This has
implications for the design of future studies undertaken to
examine the transmission dynamics of C. difficile, as the
findings may be strain and setting specific which could limit the
generalizability and use of the data generated.
The incubation period of CDI was estimated to last between
3 and 28 days but in some instances up to 12 weeks. It should
be noted that several sources of uncertainty exist when
measuring the incubation period. Estimates typically depend on
knowledge of the time / date of exposure which cannot always
be ascertained, particularly for an infection which may be
carried asymptomatically. Secondly, estimates are subject to
the assumption that transmission arose from the first traceable
contact. Even where typing studies show the same strain
between patient contacts, there is still uncertainty as to whether
transmission occurred as a result of direct patient contact or
indirect contact with other potential sources.
The only conclusion that could be drawn on contact patterns
is that with every additional day of ward contact with C. difficile-
infected patients, there is an 11% increase in the risk of
infection acquisition. There was no information on the
frequency and intensity of contacts between patients or
between members of the community that provided the
opportunity for C. difficile transmission to occur. The
information found on patient contacts would be insufficient to
inform the contact WAIFW (who acquired infection from whom)
matrix required for modelling, but is relevant to control policies
which call for the use of isolation as an intervention to curtail
the risk of C. difficile transmission in hospitals.
Serial intervals reported varied from less than one week to
186 days. Despite the variation in study settings, the lower
limits of the serial intervals reported by both studies are
comparable. This might be due to the fact that the risk of
transmitting C. difficile between spouses in a house and
patients in a shared ward depend on the same principles in
terms of contact with contaminated surfaces. It should be noted
that Pepin’s household study did not utilise molecular typing to
confirm the identity of strains responsible for index cases and
secondary cases so linkage cannot be assumed. This might
explain the unusually long serial interval of up to 186 days
estimated in this study [20].
There was a paucity of data on recovery. Observational
studies do not always follow up all infected cases to record
long term outcomes of infection, including complete recovery.
Most of the studies included in this review relied on
retrospective hospital data where recovery as an outcome may
not have been documented. Had we aimed to look at the
effects of the treatments used for CDI, more information on
recovery rate may have been found, but that was beyond the
scope of this review.
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Only two studies had adequate definitions of recurrence of
CDI. These allowed for recurrence being due to either relapse
of the primary infection or re-infection / new infection with a
different strain [34,59]. The proportion of recurrences caused
by these different possibilities will vary from cohort to cohort,
potentially influenced by, for example, treatment efficacy and
infection control precautions. Other (n=17) studies used the
terms recurrence and relapse interchangeably and others did
not clearly define these terms (n=27) [72].
The studies evaluated in this review were subject to
methodological weaknesses which suggest that this field of
research has some inherent difficulties. CDI is influenced by
multiple potentially confounding factors (e.g. patient age,
presence of co-morbidities, medication history and duration of
inpatient stay), but these were not considered in many studies.
Such residual confounding may partially explain some
differences in findings among studies reporting similar
parameters. All but thirteen studies estimated parameters using
retrospective data [25,29,32,35,39,41,43,53,55,61-63,66]. This
might explain inadequacies in outcome definitions in these
studies since the data used were initially assembled for other
purposes. Varying diagnostic techniques were used across all
studies which further limits the generalizability of individual
study findings. Diagnosis of CDI by looking for faecal C. difficile
toxins only, has sub-optimal sensitivity and is generally
considered to be insufficient as a stand-alone test for CDI. A
combined two-test algorithm involving glutamate
dehydrogenase preliminary screen or PCR for toxin gene,
followed by toxin detection is recommended for use in England
for greater sensitivity, specificity [73]. Standardisation of
diagnostic approaches would be appropriate for future studies.
Strengths and limitations of this review
Our literature search was extensive with over 7,000 studies
screened to identify potentially relevant articles. Study
selection, data extraction and study quality assessment were
all performed in duplicate to ensure consistency and reduce the
potential for bias, particularly where subjective judgement was
required. The authors conducted this review in accordance with
PRISMA and the Centre for Reviews and Dissemination (CRD)
guidelines. However, our ability to draw conclusions was
limited by the number and quality of studies found, the limited
reported detail and the heterogeneity of the included studies
(which precluded statistical synthesis of the evidence to
generate pooled estimates of parameters). The narrative
analyses were limited mainly to epidemiological studies, and
thus some of the findings (e.g. recovery rate) may not be
comparable to results obtained from clinical trials on the
effectiveness of various CDI treatments where definitions may
differ. The differential use of transmission / mathematical
modelling terminologies may have also limited our ability to
identify all studies reporting the above parameters, although
the extensive reference and citation tracking of relevant papers
will have made this unlikely. This review was designed to
identify only studies which specifically reported one or more of
the quantitative estimates required. It is likely that this tight
constraint will have excluded studies that report data which
could be used to calculate these parameters but which don’t
explicitly describe them. Recognising this, the next step of this
work will be to systematically review the epidemiological study
data in order to calculate these estimates. Nonetheless, this
and further reviews may potentially be biased by the variability
in how CDI is defined and diagnosed. The diagnostic
methodologies have evolved over time with inconsistent
sensitivity, specificity and predictive values which may
compromise the comparability of results. This has implications
for the development of mathematical models for CDI. For
example, the incubation period assumes a date of inoculation
resulting in infection; however this date is not necessarily clear
for some infections, including CDI. It is thought that
approximately 3% of the adult population carry the organism,
but it is possible that these estimates are compromised by our
current capacity to detect colonisation. Some of the included
studies utilised data from children with apparent CDI as young
as a month old. The validity of this could be questioned as
colonisation without disease has been noted in as many as
70% of neonates [74]. However, pseudomembranous colitis
associated with Clostridium difficile has been noted before in
young babies [75].
A potential criticism could be that the research did not
differentiate between mathematical parameters for community
and hospital associated or acquired disease as the setting may
influence the estimate for each parameter due to potentially
different infection dynamics by setting. However, the purpose
of the work was to elucidate all published estimates of infection
parameters for Clostridium difficile, such that they could be
utilised in models at a later date, which may or may not be
adjusted to take account of setting according to the evidence
on the importance of setting as a variable. It should be noted
that recent research has suggested that our previous
assumptions about the importance of ‘in hospital’ transmission
and acquisition in the hospital setting have been thrown into
doubt, given that only 25% of cases occurring in the hospital
studied appeared to have an links to other cases in the hospital
[2].
Our research was limited to human studies. It was beyond
the scope of the work to consider animal based studies;
however, this may have compromised the capacity to find
suitable mathematical parameters as animal based models of
the disease have been developed. Repeating this systematic
review with animal models may be an area for future research.
Conclusions
Mathematical models are increasingly being used to improve
infectious disease control. The studies identified for this review
suggest that the dynamics of human-human transmission of C.
difficile are uncertain and provide insufficient evidence for
creating a simple SEIRS type mathematical model of CDI.
Well-designed prospective transmission studies are
warranted. To establish transmission and acquisition
parameters, including the serial interval, basic reproduction
number and force of infection, studies would need to explore
the linkage between primary and secondary cases. Given that
this review has found that the reproduction rate may be
different between strains, and that these can each be carried at
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variable rates in community and hospital settings, modelling
studies may need to consider the possibility that strains can
exhibit different transmission dynamics depending on the
microbial burden and toxin concentrations they invoke in the
host and any cross-strain protection that may be present.
Additionally such studies may need to consider the setting. In
seeking to elucidate the evidence base for the mathematical
parameters that can be used to describe and model CDI, we
have not differentiated between settings (e.g. acute hospital,
community, care home). As this review has indicated, the
transmission patterns of Clostridium difficile are not completely
clear. Intuitively it might be assumed that they are different
depending on the setting, however until the scientific
understanding of the spacial and temporal relationships of
organism acquisition prior to causing symptomatic infection are
more clearly understood, this cannot be assumed. Nonetheless
it may be appropriate to consider adjusting for setting in any
future model development.
Future studies investigating CDI will necessitate clear,
consistent definitions and molecular typing / whole genome
sequencing. This is particularly relevant in the ascertainment of
relapse versus re-infection and may also help to elucidate the
prevalence, longevity and specificity of any immunity to C.
difficile. Characterising population susceptibility and its
modification with antimicrobial treatment, gut flora and IgG
antibody to C. difficile strains is also important for interpreting
reproduction rates in the modelling of outbreaks and the
potential for this to vary between cohorts. CDI testing
algorithms with higher sensitivity and specificity, positive and
negative predictive value would improve the accuracy of
diagnosis and hence the identification of C. difficile-infected
individuals to inform these parameters. Future studies could
include the screening of patients at hospital admission to
determine rates of carriage and the propensity for hosts with
asymptomatic carriage to infect others (however the positive
and negative predictive value of testing methods becomes
critical where the underlying prevalence is expected to be low).
The need for more rigorous evidence on C. difficile
transmission dynamics is particularly important given the
burden of CDI. Further empirical evidence to quantify
mechanistic transmission models could assist in controlling this
organism and inform robust infection control or healthcare
policy. Research in this area by experienced infectious disease
modellers is overdue.
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